Resminostat CAS: 864814-88-0

CAS NO: 864814-88-0
Resminostat
Chemical Name: 4SC-201
Molecular Formula: C16H19N3O4S
Formula Weight: 349.4
CAS No.: 864814-88-0
Description Review
Description

Resminostat is a small molecule histone deacetylase (HDAC) inhibitor that has been investigated for its potential therapeutic use in cancer treatment. It was developed by 4SC AG and is currently in clinical trials for liver cancer and other malignancies. Resminostat's chemical name is N-(4-(hydroxycarbamoyl)phenyl)-4-(pyridin-3-yl)benzamide, and its molecular formula is C19H16N4O3. The product has a formula weight of 348.35 g/mol and a CAS No of 864814-88-0.

Top Ten Keywords and Synonyms:

  1. Resminostat mechanism
  2. Resminostat dosage
  3. Resminostat safety
  4. Resminostat side effects
  5. Resminostat benefits
  6. HDAC inhibitor
  7. Cancer treatment
  8. 4SC AG drug
  9. Liver cancer treatment
  10. Histone acetylation

Health Benefits: Resminostat has potential benefits in cancer treatment, specifically in inhibiting tumor cell growth and promoting apoptosis (cell death). It has been shown to enhance the effectiveness of chemotherapy and radiation therapy in preclinical studies. Clinical trials have demonstrated that resminostat can improve progression-free survival and overall survival rates in patients with advanced hepatocellular carcinoma (HCC).

Potential Effects: The primary effect of resminostat is the inhibition of HDAC activity, which promotes histone acetylation and changes gene expression patterns. This leads to the regulation of key signaling pathways involved in cell proliferation, differentiation, and apoptosis. By targeting these pathways, resminostat can slow down or stop tumor growth and promote cancer cell death.

Product Mechanism: Resminostat is an HDAC inhibitor that targets class I and II HDACs, leading to increased histone acetylation and altered gene expression. This alteration in gene expression can lead to the upregulation of genes involved in apoptosis and the downregulation of genes involved in cell proliferation and angiogenesis. By altering these pathways, resminostat can inhibit tumor growth and induce programmed cell death.

Safety: In clinical trials, resminostat has been generally well-tolerated by patients, with no reported serious adverse events. However, like all drugs, there are potential risks associated with its use. Patients with liver or kidney disease, as well as those taking certain medications, should consult with their healthcare provider before using resminostat.

Side Effects: The most common side effects reported in clinical trials were fatigue, nausea, vomiting, and diarrhea. These side effects were generally mild to moderate in severity and resolved without intervention. Other less common side effects included thrombocytopenia (low platelet count), anemia (low red blood cell count), and neutropenia (low white blood cell count).

Dosing Information: The recommended dose of resminostat varies depending on the type of cancer being treated and the stage of the disease. In clinical trials for liver cancer, the typical dose was 600 mg/day, taken orally. Dosing adjustments may be necessary in patients with renal or hepatic impairment. It is important to follow your healthcare provider's instructions regarding dosing and administration of resminostat.

Conclusion: Resminostat is a promising drug for the treatment of cancer, specifically hepatocellular carcinoma. Its inhibition of HDAC activity leads to altered gene expression and the promotion of programmed cell death. While resminostat has been generally well-tolerated in clinical trials, patients should consult with their healthcare provider before using this medication. With further research, resminostat may prove to be a valuable addition to the treatment options available for cancer patients

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us